Bank of Montreal’s Structure Therapeutics GPCR Stock Holding History

Bank of Montreal’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.28M	Buy	42,570 +2,586	+6%	+$114K	﹤0.01%	1686
2026 Q1	$1.93M	Sell	39,984 -14,357	-26%	-$983K	﹤0.01%	1683
2025 Q4	$3.68M	Sell	54,341 -6,381	-11%	-$261K	﹤0.01%	1450
2025 Q3	$1.7M	Buy	60,722 +2,649	+5%	+$52.8K	﹤0.01%	1727
2025 Q2	$1.22M	Buy	58,073 +4,838	+9%	+$106K	﹤0.01%	1803
2025 Q1	$921K	Buy	53,235 +3,062	+6%	+$75K	﹤0.01%	1863
2024 Q4	$1.36M	Buy	50,173 +3,671	+8%	+$130K	﹤0.01%	1723
2024 Q3	$1.94M	Buy	46,502 +19,408	+72%	+$750K	﹤0.01%	1704
2024 Q2	$1.44M	Buy	+27,094	New	+$1.11M	﹤0.01%	1828

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Bank of Montreal's GPCR Position: Q2 2026 in Review

Bank of Montreal increased its Structure Therapeutics (GPCR) stake by 6.5% in Q2 2026, buying an estimated $114K and bringing the position to 42,570 shares worth $2.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1686.

Bank of Montreal first reported a position in GPCR in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.68M in Q4 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

Bank of Montreal held 42,570 shares of Structure Therapeutics worth $2.28M as of Q2 2026.
Bank of Montreal bought 2,586 Structure Therapeutics shares in Q2 2026, an estimated $114K.
Structure Therapeutics made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #1686 holding.
Bank of Montreal first reported a position in Structure Therapeutics in Q2 2024 and has held it in 9 quarters since.
Bank of Montreal's Structure Therapeutics position peaked at $3.68M in Q4 2025.
191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.